AFP and hepatocellular carcinoma: The miR-485-5p outperformed AFP in predicting prognosis in HCC patients by distinguishing between early and late stages of BCLC, with higher AUC, sensitivity, and specificity (0.872, 85.19, and 82.61 versus 0.695, 62.96, and 60.87, respectively) (Fig. 5) (Supplementary Table 2).